Brammer Bio, a cell and gene therapy contract development and manufacturing organization, is on track to complete the establishment of commercial-ready gene therapy manufacturing capacity in Cambridge, Massachusetts, in the second half of 2017.

This follows the January 1, 2017 acquisition of Biogen’s biologics manufacturing facility in Cambridge and distribution center in Somerville, Massachusetts, that included the on-boarding of 100 employees. Further, Brammer completed an FDA Type-C meeting to review the design plans for the Cambridge facility and will submit a site-master ile later this year to support its clients’ product applications.

Originally built for the manufacture of Biogen’s clinical and commercial biologics, the 66,000 square-foot Cambridge facility was licensed by regulatory authorities to manufacture four commercial products. Brammer is renovating the facility for late-stage clinical development and commercial launch of gene therapy products. Brammer also acquired Biogen’s nearby 49,000-square-foot distribution and warehousing facility,

Brammer, which has more than 250 employees, offers process development, clinical phase, and cGMP services for cell and gene therapies using multiple platform technologies. Since completing a merger with Florida Biologix, an Ampersand Capital Partners’ portfolio company, in March 2016, Brammer has doubled its capacity for process development and is expanding its clinical production space in Alachua, Florida. The addition of the Massachusetts facilities gives Brammer 230,000 square feet of development, distribution, and CGMP manufacturing facilities. Brammer had previously announced plans to build out its 50,000-square-foot facility in Lexington, Massachusetts, which is currently being designed for late-stage and commercial cell-therapy supply.

Source: Brammer Bio